38.86
price down icon1.79%   -0.71
after-market Handel nachbörslich: 38.89 0.03 +0.08%
loading
Schlusskurs vom Vortag:
$39.57
Offen:
$39.57
24-Stunden-Volumen:
317.26K
Relative Volume:
0.61
Marktkapitalisierung:
$1.87B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.83%
1M Leistung:
+19.35%
6M Leistung:
+186.79%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$38.56
$39.80
1-Wochen-Bereich:
Value
$38.10
$42.50
52-Wochen-Spanne:
Value
$6.71
$43.29

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name
Firmenname
Maze Therapeutics Inc
Name
Telefon
(650) 850-5070
Name
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Name
Mitarbeiter
125
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
MAZE's Discussions on Twitter

Vergleichen Sie MAZE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MAZE
Maze Therapeutics Inc
38.86 1.90B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-04 Eingeleitet Wells Fargo Overweight
2025-11-14 Eingeleitet Raymond James Outperform
2025-09-02 Eingeleitet BTIG Research Buy
2025-07-23 Eingeleitet H.C. Wainwright Buy
2025-07-08 Eingeleitet Wedbush Outperform

Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten

pulisher
Dec 13, 2025

Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen - MarketBeat

Dec 13, 2025
pulisher
Dec 11, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2%Time to Sell? - MarketBeat

Dec 11, 2025
pulisher
Dec 11, 2025

CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE - MarketBeat

Dec 11, 2025
pulisher
Dec 07, 2025

Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ

Dec 07, 2025
pulisher
Dec 06, 2025

Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq

Dec 06, 2025
pulisher
Dec 05, 2025

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World

Dec 05, 2025
pulisher
Dec 04, 2025

Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada

Dec 04, 2025
pulisher
Dec 04, 2025

A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - setenews.com

Dec 04, 2025
pulisher
Dec 04, 2025

MAZE Crosses Above Average Analyst Target - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada

Dec 04, 2025
pulisher
Dec 03, 2025

HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq

Dec 03, 2025
pulisher
Dec 03, 2025

MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView

Dec 03, 2025
pulisher
Dec 03, 2025

MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView

Dec 03, 2025
pulisher
Dec 02, 2025

Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025
pulisher
Dec 02, 2025

Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World

Dec 02, 2025
pulisher
Nov 29, 2025

Maze Therapeutics stock hugs flat line following $140M IPO - MSN

Nov 29, 2025
pulisher
Nov 28, 2025

Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView

Nov 28, 2025
pulisher
Nov 27, 2025

What dividend safety score for Maze Therapeutics Inc. stockMarket Sentiment Report & Technical Confirmation Trade Alerts - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

How Maze Therapeutics Inc. stock benefits from tech adoption2025 Geopolitical Influence & Weekly Setup with High ROI Potential - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 21, 2025

Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4%Should You Buy? - MarketBeat

Nov 20, 2025
pulisher
Nov 19, 2025

Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Maze Therapeutics Inc. stock recession proofJuly 2025 PostEarnings & Safe Capital Investment Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Maze Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Heatmap analysis for Maze Therapeutics Inc. and competitorsLong Setup & Consistent Income Trade Ideas - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Maze Therapeutics Inc. stock deliver consistent dividendsStock Surge & AI Based Buy and Sell Signals - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Applying chart zones and confluence areas to Maze Therapeutics Inc.Entry Point & Long-Term Safe Return Strategies - newser.com

Nov 18, 2025
pulisher
Nov 16, 2025

Can you recover from losses in Maze Therapeutics Inc.Quarterly Profit Report & Free Safe Capital Growth Stock Tips - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Pattern recognition hints at Maze Therapeutics Inc. upsideJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Is Maze Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Nov 16, 2025
pulisher
Nov 15, 2025

Will Maze Therapeutics Inc. outperform the marketOptions Play & High Win Rate Trade Tips - newser.com

Nov 15, 2025

Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)

Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):